The Louisiana Senate voted to pass SB 483, authored by Senator Mike Reese, a bill that would modify the composition and appointment process of the Louisiana Board of Pharmacy by adjusting pharmacist representation, expanding participation from other healthcare providers, and establishing a new appointment structure for Board membership. The bill was then referred to the House Health and Welfare Committee, where it is currently pending.
Under current law (La. R.S. 37:1172 and 1173), the Board is composed of 16 pharmacist members, with two members elected from each of the state’s eight pharmacy districts and appointed by the governor from a slate of nominees, along with one consumer representative. SB 483 maintains a total of 17 members but reduces pharmacist representation to eight members, with one elected from each district, and supplements the Board with eight additional licensed healthcare professional members.
As originally filed, those additional seats included three sterile compounding pharmacists, one chain pharmacist, one hospital pharmacist, one independent community pharmacist, one physician, and one registered nurse, while retaining the consumer representative who serves at the pleasure of the governor.
However, the version that ultimately passed the Senate reflects significant amendments adopted on the floor following changes proposed by the Senate Health and Welfare Committee. Most notably, those amendments revise the composition of the eight healthcare professional seats by eliminating the specifically designated physician and registered nurse positions and replacing them with two at-large members who must be either licensed pharmacists or other licensed healthcare professionals with prescriptive authority, each representing defined groupings of pharmacy districts. The amendments also broaden the compounding pharmacist category from “sterile compounding pharmacists” to “compounding pharmacists” generally, expanding the pool of eligible appointees.
Senator Reese cited the continued growth and increasing regulatory significance of the compounding pharmacy sector in Louisiana as a key rationale for including multiple compounding pharmacist positions on the Board.
For pharmacists and other stakeholders, this shift reduces the number of pharmacist-only seats from sixteen to eight while standardizing the remaining seats into broader, more flexible categories rather than fixed profession-specific roles.
Equally significant, the amendments overhaul the bill’s implementation timeline. As originally filed, SB 483 contemplated a phased transition tied to existing term expirations, allowing certain members to serve out their terms while gradually introducing the new Board composition. The amended version instead adopts a full reset approach: all current Board members will be removed as of June 30, 2026, and the governor will appoint an entirely new 17-member Board by July 1, 2026, with the option to reappoint existing members. For this initial appointment cycle, district pharmacist members will be appointed directly by the governor without the usual nomination and election process set forth in La. R.S. 37:1175(B), and all appointments will be subject to Senate confirmation during the 2027 Regular Session.
The current version of the bill also requires the governor to fill vacancies for the consumer member and the appointed healthcare professional members within 60 days and establishes a two-term limit for all Board members. Importantly, the bill does not change the length of Board member terms. Consistent with current law (La. R.S. 37:1177(A)), members will continue to serve six-year terms beginning July 1 of the year of appointment.
We will continue to monitor the bill as it moves through the legislative process and will provide updates regarding any additional amendments, as well as implementation if the bill is enacted. As of the date of this publication, the SB 483 has not been scheduled for a hearing in House Health and Welfare.
